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Physiologic roles of highly phosphorylated inositol phosphates, including those containing
pyrophosphate groups, have been the focus of much recent interest. In the April 6, 2007 issue of
Science, two papers (Lee et al., 2007; Mulugu et al., 2007) demonstrate the occurrence of a novel
inositol pyrophosphate molecule in yeast and elucidate its role in phosphate homeostasis.Cell Metabolism 5, May 2007 ª2007 Elsevier Inc. 321The inositol pyrophosphates possess
energetic b-phosphates that phos-
phorylate proteins. Now, Lee et al.
(2007) and Mulugu et al. (2007) report
a chemically distinct inositol pyro-
phosphate with potentially novel sig-
naling capacities.
Inositol hexakisphosphate (IP6) or
phytic acid is the principal storage
phosphate in plant seeds. In 1993,
two inositol pyrophosphates were
identified, diphosphoinositol penta-
kisphosphate (PP-IP5, or IP7) and bis-
diphosphoinositol tetrakisphosphate
([PP]2-IP4, or IP8) (Bennett et al.,
2006), which contain one and two py-
rophosphates, respectively (Figure 1).
PP-IP5 present in mammals was later
shown to possess a pyrophosphate
moiety at the C5 position. Generation
of 5-PP-IP5 involves a family of IP6
kinases (IP6Ks), one in yeast and three
in mammals (Saiardi et al., 1999).
Inositol pyrophosphates have many
functions. In yeast, deletion of IP6K
(yIP6K), also designated Kcs1, leads
to a decreased ability to accumulate
inorganic phosphate; major defects in
vesicular trafficking; and alterations in
DNA recombination, telomere length,
and stress response (Bennett et al.,
2006). In mammals, one of the en-
zymes, IP6K2, is associated with cell
death, as its depletion greatly reduces
cell death elicited by diverse stressors
and its overexpression sensitizes cells
to apoptotic actions of several anti-
cancer drugs.
The molecular mode of signaling for
5-PP-IP5 has been unclear. Signaling
may utilize a novel form of protein
phosphorylation in which the b-phos-phate of IP7 is donated to proteins
in an autocatalytic fashion (Saiardi
et al., 2004). As this process requires
prior phosphorylation, it appears to
reflect protein pyrophosphorylation
(R.B. and S.H.S. unpublished data).
In regulating chemotaxis by the slime
moldDictyostelium discoideum, 5-PP-
IP5 signaling does not involve phos-
phorylation (Bennett et al., 2006).
It has generally been assumed that
all of the PP-IP5 in yeast is synthesized
by yIP6K (Kcs1), the only yeast mem-
ber of the IP6K gene family heretofore
identified (Saiardi et al., 1999). More-
over, in S. cerevisiae lacking yIP6K,
PP-IP5 is no longer generated from
[3H]inositol (Bennett et al., 2006). How-
ever, a new form of PP-IP5 in addition
to 5-PP-IP5 appears following dele-
tion of the PP-IP pyrophosphatase in
S. pombe (Ingram et al., 2003). More-
over, IP7 reappears upon deletion of
the PP-IP pyrophosphatase (Ddp1 in
S. cerevisiae) in yIP6K-deficient yeast,
implying the existence of another IP6K
that generates a pool of PP-IP5 that is
rapidly degraded by Ddp1 under basal
conditions (York et al., 2005). Mulugu
et al. (2007) have identified a novel
IP6 kinase corresponding to a known
yeast protein, Vip1, which is unlike
any other inositol phosphate kinase
but which displays robust IP6 kinase
activity. A major surprise came via
chemical analysis, which revealed
that PP-IP5 made by Vip1 differs from
5-PP-IP5 made by yIP6K (Kcs1), as
the pyrophosphate bond in the Vip1
product is located at C4 or C6. Being
enantiomers, 4-PP-IP5 and 6-PP-IP5
cannot be distinguished by NMR,whichwas used by the authors to iden-
tify the product of Vip1. Crystallogra-
phy or an enantiomerically specific
inositol phosphate kinase/phospha-
tase might establish the physiologic
enantiomer. Using 6-PP-IP5-5-kinase
from D. discoideum as an enantio-
specific tool, Vogel and colleagues
(Laussmann et al., 1997) detected
6-PP-IP5 in Dictyostelium species.
Although the enzyme responsible for
the synthesis of 6-PP-IP5 in dictyostel-
ids has not been identified, a likely
candidate is a hypothetical protein in
D. discoideum (DDBDRAFT_0186099)
with sequence similarity to Vip1.
The ‘‘classical’’ IP6 kinases and Vip1
may work in concert to synthesize
IP8 (Figure 1). 5-PP-IP5 formed by
yIP6K (Kcs1) is further phosphorylated
by Vip1 to form IP8 (Mulugu et al.,
2007). Conversely, 4/6-PP-IP5 formed
by Vip1 is acted upon by IP6K to
form IP8. An enzyme that selectively
transforms 5-PP-IP5 to IP8 was puri-
fied, but not cloned (Huang et al.,
1998), and its relationship to Vip1 is
unclear.
Independently, O’Shea and col-
leagues have for many years studied
how yeast regulate phosphate accu-
mulation (Lenburg and O’Shea, 1996).
Key elements include a secreted acid
phosphatase that releases inorganic
phosphate and high-affinity phos-
phate transporters, both of which are
regulated by the transcription factor
Pho4.With abundant phosphate, Pho4
is exported from the nucleus due to
its phosphorylation by a cyclin/cyclin-
dependent kinase (CDK) complex
(Pho80-Pho85). Upon phosphate
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PreviewsFigure 1. Inositol Pyrophosphates Regulate Multiple Physiological Processes
IP3 released by PIP2 hydrolysis is converted by a series of inositol phosphate kinases to IP4, IP5, and IP6. IP6 is the precursor for two forms of
PP-IP5, or IP7: 4/6-PP-IP5, synthesized by Vip1, and 5-PP-IP5, synthesized by IP6K. PP-IP5 synthesized by one enzyme can be converted to
[PP]2-IP4, or IP8, by the other enzyme. Over the years, several functions have been ascribed to 5-PP-IP5 (Bennett et al., 2006), whereas 4/6-PP-
IP5 has recently been identified in yeast and is involved in regulating cell morphology, cell growth, and phosphate homeostasis (Lee et al., 2007;
Mulugu et al., 2007).starvation, the cyclin-CDK complex
is inhibited, leading to nuclear accu-
mulation of dephosphorylated Pho4,
transcription of phosphate-responsive
genes, and phosphate uptake. Regu-
lation of cyclin-CDK activity by phos-
phate levels requires a CDK inhibitor
protein (CKI), Pho81. However, since
CKI is constitutively bound to the
cyclin-CDK complex regardless of in-
tracellular phosphate levels, themech-
anism of regulation of Pho4 phos-
phorylation by phosphate levels was
not understood. Lee et al. (2007) have
found that the kinase activity of the
cyclin-CDK-CKI complex purified from
cells grown under high-phosphate
conditions can be inhibited by a small
molecule (<3 kDa) found in lysates
from cells grown under phosphate
starvation. This inhibitor was purified
to homogeneity and identified as 4/6-
PP-IP5. Whereas 4/6-PP-IP5 inhibits
cyclin-CDK kinase activity, 5-PP-IP5
is inactive.
Why did nature create two distinct
forms of PP-IP5? While 5-PP-IP5 acts
by both binding and phosphorylation322 Cell Metabolism 5, May 2007 ª2007of proteins, it remains to be seen
whether 4/6-PP-IP5 can transfer its
b-phosphate moiety to proteins. Both
forms of PP-IP5 regulate phosphate
uptake, which in addition to being
regulated by Vip1 (Lee et al., 2007) is
substantially reduced in yeast lacking
yIP6K (Kcs1) (Saiardi et al., 2004).
What might be the physiologic roles
of 4/6-PP-IP5 in mammals? Twomam-
malian orthologs of Vip1 exist, but they
have not been associated with any
known function. In the yeastS. pombe,
4/6-PP-IP5 is generated by an ortholog
of Vip1 called Asp1, which modulates
the actin cytoskeleton by regulating
actin-related protein (Arp) complexes
and hence cell growth and morphol-
ogy (Mulugu et al., 2007). Although
the Arp proteins are conserved across
species and are involved in develop-
ment, morphogenesis, and cell motil-
ity in mammals, it is unclear whether
4/6-PP-IP5 regulates these processes
in mammals. The mammalian type III
sodium-dependent phosphate co-
transporters PiT1 and PiT2 are
regulated by extracellular phosphateElsevier Inc.(Kavanaugh et al., 1994) and resemble
a yeast sodium-coupled phosphate
transporter (Pho89). Therefore, phos-
phate homeostasis in mammalian tis-
sues might be regulated by inositol
pyrophosphates in a manner similar to
the regulation of the yeast phosphate
response pathway. The mammalian
IP6K isoform, IP6K2, was originally
identified as PiUS (inorganic phos-
phate uptake stimulator), which aug-
ments phosphate uptake (Bennett
et al., 2006).
Phosphate accumulation is critical
for classical biochemical pathways
including sugar metabolism and pro-
tein phosphorylation. Of comparable
quantitative importance but less ap-
preciated by the scientific community
are the abundant inorganic polyphos-
phates, characterized extensively by
Arthur Kornberg and colleagues (Korn-
berg et al., 1999). Deletion of yIP6K
(Kcs1) leads to depletion of polyphos-
phates (Bennett et al., 2006), while the
influence of Vip1 is unknown. Poly-
phosphates are important in mamma-
lian physiology, occurring in millimolar
Cell Metabolism
Previewsconcentrations in platelets, where they
regulate the clotting process (Smith
et al., 2006).
The serendipitous concatenation of
efforts by the York and O’Shea labora-
tories (Mulugu et al., 2007; Lee et al.,
2007) enhances our appreciation of
inositol pyrophosphate biology. Differ-
ential roles for the two forms of PP-IP5
remain a mystery. However, it is ‘‘early
in the game,’’ and inositol pyrophos-
phates have already been implicated
in many processes fundamental to
life. The future is bright.
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An emerging view is that obesity
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Obesity is an important risk factor
in a complex metabolic syndrome
characterized by insulin resistance,
dyslipidemia, and hypertension and
is associated with diabetes and car-
diovascular complications. Current
pharmacological and behavioral ther-
apeutic strategies have had limited
success in controlling the prevalence
of obesity. Given the urgency of the
problem and the somber prospects
ahead, new strategies are required
to prevent the deleterious metabolic
effects associated with obesity.
There is little doubt that obesity
results from a positive imbalance
between energy intake and energy
expenditure. However, it is less clear
why being obese leads to diabetes
and cardiovascular complications. AnREFERENCES
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emerging view is that obesity causes
metabolic problems when adipose
tissue fails to meet the increased
demands for fat storage. Under these
circumstances, the excess fat that
cannot be efficiently and safely stored
in adipose tissue accumulates in other
metabolically relevant organs such as
muscle, liver, b cells, andmyocardium,
causing lipotoxicity and associated
metabolic complications.
Acceptance of the ‘‘lipotoxicity
hypothesis’’ leads to the apparently
paradoxical therapeutic approach of
promoting adipogenesis in obese in-
dividuals as a strategy to improve the
storage capacity of their adipose tis-
sue, thereby preventing the devel-
opment of complications associated
with obesity. This rationale is explored
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byWaki et al. (2007) in this issue ofCell
Metabolism. The authors performed
a high-throughput screen to identify
proadipogenic small molecules using
preadipocytes engineered with a re-
porter system activated by PPARg,
a key adipogenic transcription factor.
The idea was that small molecules
that selectively enhance PPARgwould
be identified through the activation
of this reporter. This imaginative ap-
proach paid off with the identification
of harmine.
Harmine, also known as telepathine
and banisterine, is a naturally occur-
ring b-carboline alkaloid found in
numerous plants including the Middle
Eastern plant harmal or Syrian rue (Pe-
ganum harmala), the South American
vine Banisteriopsis caapi (‘‘yage’’ or
ism 5, May 2007 ª2007 Elsevier Inc. 323
